NCT01300572View on ClinicalTrials.gov

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 29, 2017

Study Completion Date

November 22, 2019

Conditions
Chronic Myelomonocytic LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Anemia With Excess BlastsSecondary Acute Myeloid Leukemia
Interventions
PROCEDURE

Allogeneic Bone Marrow Transplantation

Undergo allogeneic bone marrow transplant

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic PBSC or bone marrow transplant

DRUG

Cyclosporine

Given PO or IV

DRUG

Fludarabine Phosphate

Given IV

BIOLOGICAL

Indium In 111 Anti-CD45 Monoclonal Antibody BC8

Given IV (dosimetric dose)

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mycophenolate Mofetil

Given PO or IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSC transplant

OTHER

Pharmacological Study

Correlative studies

RADIATION

Total-Body Irradiation

Undergo TBI

RADIATION

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

Given via central line (therapeutic dose)

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01300572 - Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS | Biotech Hunter | Biotech Hunter